Matrix stiffness regulates endosomal escape of uropathogenic E. coli

Uropathogenic E. coli (UPEC) infection in vivo is characterized by invasion of bladder umbrella epithelial cells followed by endosomal escape and proliferation in the cytoplasm to form intracellular bacterial communities. By contrast, UPEC infection in tissue culture models results in bacteria being trapped within Lamp1‐positive endosomes where proliferation is limited. Pharmacological disruption of the actin cytoskeleton has been shown to facilitate UPEC endosomal escape in vitro and extracellular matrix stiffness is a well‐characterized physiological regulator of actin dynamics; therefore, we hypothesized that substrate stiffness may play a role in UPEC endosomal escape. Using functionalized polyacrylamide substrates, we found that at physiological stiffness, UPEC escaped the endosome and proliferated rapidly in the cytoplasm of bladder epithelial cells. Dissection of the cytoskeletal signaling pathway demonstrated that inhibition of the Rho GTPase RhoB or its effector PRK1 was sufficient to increase cytoplasmic bacterial growth and that RhoB protein level was significantly reduced at physiological stiffness. Our data suggest that tissue stiffness is a critical regulator of intracellular bacterial growth. Due to the ease of doing genetic and pharmacological manipulations in cell culture, this model system may provide a useful tool for performing mechanistic studies on the intracellular life cycle of uropathogens.     

Hepatitis B Virus Replication and Release Are Independent of Core Lysine Ubiquitination

Ubiquitin conjugation to lysine residues regulates a variety of protein functions, including endosomal trafficking and degradation. While ubiquitin plays an important role in the release of many viruses, the requirement for direct ubiquitin conjugation to viral structural proteins is less well understood. Some viral structural proteins require ubiquitin ligase activity, but not ubiquitin conjugation, for efficient release. Recent evidence has shown that, like other viruses, hepatitis B virus (HBV) requires a ubiquitin ligase for release from the infected cell. The HBV core protein contains two lysine residues (K7 and K96), and K96 has been suggested to function as a potential ubiquitin acceptor site based on the fact that previous studies have shown that mutation of this amino acid to alanine blocks HBV release. We therefore reexamined the potential connection between core lysine ubiquitination and HBV replication, protein trafficking, and virion release. In contrast to alanine substitution, we found that mutation of K96 to arginine, which compared to alanine is more conserved but also cannot mediate ubiquitin conjugation, does not affect either virus replication or virion release. We also found that the core lysine mutants display wild-type sensitivity to the antiviral activity of interferon, which demonstrates that ubiquitination of core lysines does not mediate the interferon-induced disruption of HBV capsids. However, mutation of K96 to arginine alters the nuclear-cytoplasmic distribution of core, leading to an accumulation in the nucleolus. In summary, these studies demonstrate that although ubiquitin may regulate the HBV replication cycle, these mechanisms function independently of direct lysine ubiquitination of core protein.The hepatitis B virus (HBV) particle consists of an enveloped nucleocapsid that contains the viral polymerase (Pol) and an incomplete 3.2-kb double-stranded DNA genome (9). In the cytoplasm, the viral core structural proteins interact to form homodimers, which further self-assemble into capsid particles that package Pol and the viral pregenomic RNA. Encapsidated Pol subsequently reverse transcribes pregenomic RNA to give rise to mature double-stranded relaxed circular DNA-containing capsids. HBV DNA-containing capsids are released from the cell as mature virions after acquiring an envelope consisting of cellular membrane lipids and the viral small, middle, and large envelope proteins (4, 9, 41). Due to the directed insertion of the envelope proteins in the endoplasmic reticulum and Golgi membrane, and the requirement of the large envelope protein for virion release, nucleocapsids are hypothesized to bud at intracellular membranes for release through the constitutive secretory pathway (5). Although the mechanism and site of HBV nucleocapsid envelopment and release remain poorly understood, emerging evidence indicates that the cellular ubiquitin pathway may play a role in this process.Structural proteins of some enveloped RNA viruses contain highly conserved sequences [PPXY, P(T/S)AP, and YPXL] termed late (L) domains that mediate interactions with proteins of the endocytic pathway to facilitate virus budding and release (1). The P(T/S)AP motif binds Tsg101 (8, 10, 19, 27, 47), a key ESCRT (for endosomal sorting complex required for transport) component for the recognition and sorting of ubiquitinated proteins to internal vesicles of the multivesicular body (MVB), while the YPXL motif binds Alix, an ESCRT-associated protein (26, 44, 48). The PPXY motif binds proteins of the Nedd4 family ubiquitin ligases, which are responsible for ubiquitination of proteins targeted for endocytosis and sorting to the MVB (20), suggesting a link between ubiquitin and viral budding (3, 16, 17, 22, 43, 55). The observation that proteasome inhibition, which depletes free cellular ubiquitin by interfering with ubiquitin recycling, results in a viral budding defect similar to that seen in virus L domain mutants further supports the implication that ubiquitin plays a role in mediating virion release (15, 31, 40, 43). Furthermore, fusion of ubiquitin to the Rous sarcoma virus (RSV) PPPY-containing Gag protein and the equine infectious anemia virus (EIAV) Gag protein containing a heterologous PTAP or PPPY motif rescues the virus-like particle release defect induced by proteasome inhibition (18, 31). While the role of L domains in mediating virion release is relatively well established, it remains unclear whether direct ubiquitination of viral structural proteins is generally required for virion release. Mutation of ubiquitin acceptor lysine residues in the RSV Gag protein inhibits virus budding, but such mutations in human immunodeficiency virus type 1 (HIV-1) or murine leukemia virus Gag protein exert no effect on virus release (29, 42). Recently, a retroviral (i.e., prototypic foamy virus) Gag protein engineered to lack ubiquitin acceptor lysines and encoding either the PSAP or PPXY motif of the L domain displayed no defect in viruslike particle release (58). Altogether, these results suggest that recruitment of host proteins to the L domain and ubiquitination of interacting proteins, but not the viral structural proteins, is required for ubiquitin-dependent virion release, at least for some viruses.The HBV core structural protein contains two potential ubiquitin acceptor lysine residues (K7 and K96) and an L-domain-like PPAY motif (Fig. ​(Fig.1A).1A). Structural studies indicate that residue K96 and the PPAY motif may be exposed on the surface of HBV capsid particles, at least transiently (4, 32, 37). Studies aimed at identifying interaction factors important for HBV particle release demonstrated a number of interesting findings. First, γ2-adaptin, a cellular trafficking adaptor that contains a ubiquitin-interacting motif (UIM), interacts with both the viral large envelope protein and HBV core, and disruption of the HBV/γ2-adaptin interaction inhibits virus secretion (14, 39). Second, core protein interacts with the Nedd4 ubiquitin ligase through the PPAY motif in core (39). Mutation of the tyrosine in the PPAY motif results in disrupted binding of Nedd4, and overexpression of a catalytically inactive Nedd4 mutant inhibits HBV particle secretion (39). Third, mutation of core K96, but not K7, to alanine results in a defective release phenotype, suggesting that K96 may serve as a ubiquitin conjugation site that aids virion release (32, 39). Recently, overexpression of dominant-negative proteins of the MVB machinery, such as the Vps4 ATPases and the ESCRT-III complex-forming CHMP proteins, were also shown to disrupt HBV budding and virion release, while subviral particles comprised only of envelope proteins were released efficiently (21, 24, 49). This suggests that nucleocapsids may release from the cell by a mechanism distinct from constitutive secretion. These studies show that similar to RNA viruses, HBV utilizes components of the cellular protein trafficking machinery to mediate virion release.Open in a separate windowFIG. 1.Generation of core lysine mutants. (A) The 21-kDa HBV core structural protein contains two lysine residues at positions 7 and 96 that serve as potential ubiquitin conjugation sites. These residues are highly conserved among the four major HBV genotypes (6). Core contains a late-domain-like PPXY motif that serves as a binding site for the Nedd4 E3 ubiquitin ligase. Core additionally contains a potential noncanonical SUMOylation motif at position 96. (B) Lysine mutations were generated by site-directed mutagenesis in the core gene contained within the HBV genome under the control of a CMV promoter. K7R contains a lysine-to-arginine mutation at position 7, K96R contains a lysine-to-arginine mutation at position 96, K96A contains a lysine-to-alanine mutation at position 96, and K7R/K96R contains arginine substituted at position 7 and position 96.Although these findings imply that core ubiquitination may be necessary for HBV particle release, direct evidence of core ubiquitination has been elusive (33, 39; unpublished results). As suggested by previous Gag lysine mutagenesis studies, however, ubiquitin may instead indirectly be required through conjugation to an interacting protein that is essential for mediating HBV release (29, 58). Although core K7 and K96 have been previously assayed in the context of virion release by mutation of the lysine residues to alanine (32, 39), we expanded these studies by assaying core mutants with an arginine substitution at position K7 (K7R) and K96 (K96R), as well as a double lysine-to-arginine mutation (K7R/K96R). Compared to alanine, arginine serves as a more conserved mutation for lysine while still abolishing the potential ubiquitin conjugation site. In the present study, we utilized these mutants to comprehensively examine the role of the core lysines in HBV virus release, the formation of replication intermediates, intracellular localization of core, and the interferon (IFN)-mediated antiviral response.     

Lateral signaling enhances TGF-beta response complexity

TGF-beta elicits context-dependent and cell-specific effects that often appear conflicting, such as stimulation or inhibition of growth, apoptosis or differentiation. It is puzzling how such a diverse array of responses can result from binding of TGF-beta to a single receptor complex that activates a seemingly straightforward signal-transduction scheme dependent on shuttling of Smad transducer proteins from the receptor to the nucleus. Here, we discuss a novel paradigm for TGF-beta signaling in endothelial cells in which the same ligand can induce opposing effects mediated by activation of two different classes of Smads through a chimeric receptor complex.     

New species of Balantidium and Paracichlidotherus (Ciliophora) inhabiting the intestines of four surgeonfish species from the Tuvalu Islands,Pacific Ocean

Four species of adult herbivorous surgeonfishes (Family Acanthuridae) were collected from the remote South-Pacific island system of Tuvalu. Their intestinal contents were examined, and of four populations of ciliated protists, two new species were discovered and are described. Ciliates were examined after protargol staining and, in some cases, scanning electron microscopy. Members of each population were examined and 10 characters measured for the balantidia, and 13 for the paracichlidotherids. A new Balantidium is described which has an unusually large dextr-oral field of cilia. A new species of Paracichlidotherus was discovered which has a macronucleus significantly smaller and well anteriad the cytoplasmic portion of the oral polykinetids relative to the type species.     

Inhibition of human alkaline phosphatase isoenzymes by the affinity reagent reactive yellow 13

The dye Reactive Yellow 13, an affinity reagent for intestinal alkaline phosphatase, inhibits intestinal and other human alkaline phosphatases in solution. The inhibition depends markedly on the presence of a phosphate acceptor such as diethanolamine. The dye is an uncompetitive inhibitor with respect to both substrate and phosphate acceptor in the case of non-intestinal phosphatases. However, in the case of intestinal alkaline phosphatase, the inhibition is noncompetitive with respect to the substrate and competitive with respect to the phosphate acceptor. These observations account for the specific binding of intestinal phosphatase when the dye is used as a ligand in affinity chromatography.     

Chiral discrimination using a quartz crystal microbalance and comparison with gas chromatographic retention data

Quartz crystal microbalances (QCMB) have been constructed using 10 MHz AT cut quartz crystals coated with heptakis(2,3,6-tri-O-methyl)-β-cyclodextrin, heptakis(6-O-methyl-2,3-di-O-pentyl)-β-cyclodextrin, and octakis(6-O-methyl-2,3-di-O-pentyl)-γ-cyclodextrin as 50% and 20% (w/w) solutions in OV1701. The reduction in frequency seen on exposure of each coated QCMB to pure enantiomeric forms of α- and β-pinene and cis- and trans-pinane show that statistically significant (P = 0.05, n = 7) differences are observed between the enantiomeric pairs. The apparent preferential binding shown by the QCMB for enanciomers of α- and β-pinene and cis- and trans-pinane have been compared with the elution order observed on the corresponding gas chromatographic stationary phase. The magnitude of the observed separation factor (calculated as the ratio of the OV1701 normalised frequency shift) is seen to be dependent upon the chiral stationary phase concentration. These results indicate that on-line determination of enantiomeric excess and concentration of certain monoterpenes is possible at room temperature using QCMB in conjunction with chiral gas chromatographic stationary phases. Chirality 9:225–232, 1997. © 1997 Wiley-Liss, Inc.     

Assessing mitochondrial outer membrane permeabilization during apoptosis

Mitochondria play a pivotal role in the regulation of apoptosis. An imbalance in apoptosis can lead to disease. Unscheduled apoptosis has been linked to neurodegeneration while inhibition of apoptosis can cause cancer. An early and key event during apoptosis is the release of factors from mitochondria. In apoptosis the mitochondrial outer membrane becomes permeable, leading to release of apoptogenic factors into the cytosol. One such factor, cytochrome c, is an electron carrier of the respiratory chain normally trapped within the mitochondrial intermembrane space. Many apoptotic studies investigate mitochondrial outer membrane permeabilization (MOMP) by monitoring the release of cytochrome c. Here, we describe three reliable techniques that detect cytochrome c release from mitochondria, through subcellular fractionation or immunocytochemistry and fluorescence microscopy, or isolated mitochondria and recombinant Bax and t-Bid proteins in vitro. These techniques will help to identify mechanisms and characterize factors regulating MOMP.     

Cathelicidin LL-37 increases lung epithelial cell stiffness, decreases transepithelial permeability, and prevents epithelial invasion by Pseudomonas aeruginosa

In addition to its antibacterial activity, the cathelicidin-derived LL-37 peptide induces multiple immunomodulatory effects on host cells. Atomic force microscopy, F-actin staining with phalloidin, passage of FITC-conjugated dextran through a monolayer of lung epithelial cells, and assessment of bacterial outgrowth from cells subjected to Pseudomonas aeruginosa infection were used to determine LL-37's effect on epithelial cell mechanical properties, permeability, and bacteria uptake. A concentration-dependent increase in stiffness and F-actin content in the cortical region of A549 cells and primary human lung epithelial cells was observed after treatment with LL-37 (0.5-5 μM), sphingosine 1-phosphate (1 μM), or LPS (1 μg/ml) or infection with PAO1 bacteria. Other cationic peptides, such as RK-31, KR-20, or WLBU2, and the antibacterial cationic steroid CSA-13 did not reproduce the effect of LL-37. A549 cell pretreatment with WRW4, an antagonist of the transmembrane formyl peptide receptor-like 1 protein attenuated LL-37's ability to increase cell stiffness. The LL-37-mediated increase in cell stiffness was accompanied by a decrease in permeability and P. aeruginosa uptake by a confluent monolayer of polarized normal human bronchial epithelial cells. These results suggested that the antibacterial effect of LL-37 involves an LL-37-dependent increase in cell stiffness that prevents epithelial invasion by bacteria.